Feasibility and Validity of the 6-Minute Cycling Test in Childhood Cancer Patients.

IF 1.2 4区医学 Q4 HEMATOLOGY

Pediatric Hematology and Oncology Pub Date : 2026-04-30 DOI:10.1080/08880018.2026.2661758

Lena Wypyrsczyk, Mareike Kühn, Elias Dreismickenbecker, Marie A Neu, Heidi Diel, Joerg Faber

{"title":"Feasibility and Validity of the 6-Minute Cycling Test in Childhood Cancer Patients.","authors":"Lena Wypyrsczyk, Mareike Kühn, Elias Dreismickenbecker, Marie A Neu, Heidi Diel, Joerg Faber","doi":"10.1080/08880018.2026.2661758","DOIUrl":null,"url":null,"abstract":"The 6-min cycling test (6MCT), a submaximal endurance test, has not yet been applied in pediatric oncology. This study evaluates its feasibility and validity in 71 childhood cancer patients (9.6 ± 4.0 years). For validation, 46 patients additionally underwent cardiopulmonary exercise testing (CPET). Performance in the 6MCT (total revolutions) was correlated with peak oxygen uptake (VO2peak) and peak work rate (WRpeak) using Spearman's correlation. Linear regressions assessed the predictive value of VO2peak and WRpeak on 6MCT performance. Sixty-six participants (93%) successfully completed the 6MCT, averaging 550 ± 129 revolutions. Revolutions correlated moderately with VO2peak (ρ = 0.46, p = 0.001) and strongly with WRpeak (ρ = 0.64, p < 0.001). VO2peak significantly predicted 6MCT performance (p = 0.001, R2 = 0.214), whereas WRpeak explained more variance (p < 0.001, R2 = 0.488). The results demonstrate that the 6MCT is a feasible, valid endurance assessment in this population, offering a promising alternative when gold standard testing is not available.","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"1-14"},"PeriodicalIF":1.2000,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2026.2661758","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The 6-min cycling test (6MCT), a submaximal endurance test, has not yet been applied in pediatric oncology. This study evaluates its feasibility and validity in 71 childhood cancer patients (9.6 ± 4.0 years). For validation, 46 patients additionally underwent cardiopulmonary exercise testing (CPET). Performance in the 6MCT (total revolutions) was correlated with peak oxygen uptake (VO₂_peak) and peak work rate (WR_peak) using Spearman's correlation. Linear regressions assessed the predictive value of VO₂_peak and WR_peak on 6MCT performance. Sixty-six participants (93%) successfully completed the 6MCT, averaging 550 ± 129 revolutions. Revolutions correlated moderately with VO₂_peak (ρ = 0.46, p = 0.001) and strongly with WR_peak (ρ = 0.64, p < 0.001). VO₂_peak significantly predicted 6MCT performance (p = 0.001, R² = 0.214), whereas WR_peak explained more variance (p < 0.001, R² = 0.488). The results demonstrate that the 6MCT is a feasible, valid endurance assessment in this population, offering a promising alternative when gold standard testing is not available.

查看原文本刊更多论文

儿童癌症患者6分钟循环试验的可行性和有效性。

6分钟循环试验（6MCT）是一种亚极限耐力试验，尚未应用于儿科肿瘤学。本研究对71例儿童肿瘤患者（9.6±4.0岁）进行可行性和有效性评价。为了验证，46例患者额外进行了心肺运动试验（CPET）。使用Spearman相关，6MCT（总转数）的表现与峰值摄氧量（VO2peak）和峰值工作速率（WRpeak）相关。线性回归评估了VO2peak和WRpeak对6MCT性能的预测价值。66名参与者（93%）成功完成6MCT，平均550±129转。转速与VO2peak （ρ = 0.46, p = 0.001）和WRpeak （ρ = 0.64, p = 0.001, R2 = 0.214）呈正相关，而WRpeak解释了更多的方差（p R2 = 0.488）。结果表明，6MCT是一种可行、有效的耐力评估方法，在没有金标准测试的情况下提供了一种有希望的替代方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Hematology and Oncology 医学-小儿科

CiteScore

2.60

自引率

5.90%

发文量

审稿时长

6-12 weeks

期刊介绍： PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.